The UK Government’s 2024 Budget, while squarely focused on tax increases and revenue measures, suggests a pragmatic recognition by the new Labour administration that sustainable tax receipts are ideally underpinned by economic growth and wealth creation. In a global economy increasingly driven by innovation, investment in intellectual property (IP) and the frameworks that support its commercialization are critical. The government’s commitment to maintaining the R&D tax credit scheme and, by implication, the Patent Box regime—key mechanisms that support the innovation ecosystem—reflects an understanding of the value these instruments bring to the economy. Preserving these tax incentives mitigates the risk of disincentivizing private sector investment, particularly for small and medium-sized enterprises (SMEs) that rely on them to offset significant R&D and patent protection costs.
The R&D tax credit scheme, which offers relief on eligible research and development expenditure, remains a central pillar of the UK’s innovation infrastructure, enabling companies to reinvest in the next generation of technologies. Although the scheme could benefit from targeted adjustments, its preservation signals an appreciation for its role as a long-term growth driver.
Likewise, the government’s decision to retain the Patent Box, allowing companies to apply a reduced corporate tax rate to profits derived from patented inventions, reinforces the UK’s commitment to supporting high-value innovation. This incentive encourages companies not only to develop IP domestically but also to retain ownership through patent protection—a vital stability point as British firms contend with heightened international competition. Strengthening the Patent Box, or at least maintaining its existing provisions, could incentivize even more companies to retain and develop IP within the UK, balancing the disproportionate share of foreign-held patents here—a figure that is the highest among G7 nations.
Globally, economies such as South Korea, Germany, and the United States provide salient examples of how strong IP frameworks can drive substantial economic returns. South Korea’s IP-oriented policy framework has enabled its businesses to secure competitive advantages through IP protection, driving the country’s remarkable growth in GDP and global innovation standing over the past four decades. In comparison, the UK’s relatively modest patent-filing rates suggest missed opportunities to fully harness its strong research and development outputs. While maintaining the R&D tax credit and Patent Box regimes is a welcome move, it remains largely passive. A more comprehensive, strategic approach would be required to maximize the UK’s innovation potential.
The absence of new measures within this budget aimed at stimulating innovation and IP protection could be seen as a missed opportunity. Yet the continuity of the R&D tax credits and the Patent Box provides a crucial foundation of stability for British businesses at a time when government demands on the private sector are growing. These innovation-led reliefs create a platform that, if leveraged more strategically, could enhance the UK’s attractiveness as a hub for IP-driven growth. To transform its world-class research outputs into economic performance, on par with other advanced economies, future government initiatives would be well-served by enhanced support and incentives that foster a more dynamic IP culture. In proactively incentivizing and protecting innovation, the UK can better position itself to thrive within the global innovation economy, generating high-value employment and promoting sustainable growth across the country.
Written by Graeme Moore
Partner and Head of Engineering, Mewburn Ellis
You may also like…
How I would use AI to steal your design… and what you can do about it
To protect our designs, ideas, and innovations, we must think like an infringer. May AI allow bad actors to knock off...
Calcutta High Court issues IP Division Rules
The Calcutta High Court recently adopted the much-awaited Intellectual Property Rights Division Rules, 2023 (Calcutta...
AstraZeneca challenges Axelpharm’s cancer drug patent
AstraZeneca is a world-renowned pharmaceutical company. It owns many patents in Russia and takes steps to protect them...
Contact us to write for out Newsletter